This article is more than 5 years old. Information may no longer be current.
Anti-VEGF yields favorable outcomes for treatment-naïve retinal vein occlusion
Br J Ophthalmol. 2011;95(1):56-68.
Click Here to Manage Email Alerts
Intravitreal ranibizumab improved visual acuity and reduced central macular thickness in eyes with treatment-naïve retinal vein occlusion, according to a study.
The prospective, non-comparative, interventional case series included 17 eyes of 17 consecutive patients who received 0.5-mg injections of Lucentis (ranibizumab, Genentech). Follow-up was conducted for at least 12 months.
The nine patients with central retinal vein occlusion had a mean best corrected visual acuity of 20/240 before treatment, which significantly improved to 20/46 at 1-year follow-up (P < .0001).
From baseline, patients with CRVO gained 6.4 lines for a mean BCVA of 36.7 letters, and central macular thickness was reduced by a mean of 360 µm to 271 µm (P < .0001), according to the study.
The eight patients with branch retinal vein occlusion had a mean BCVA of 20/126 before treatment, which significantly improved to 20/50 at 1-year follow-up (P < .0001).
From baseline, central macular thickness was reduced by a mean of 275 µm to 278 µm (P < .0001).
The treated eyes in both groups showed significant improvement in contrast sensitivity, near vision and reading fluency.
Patients with CRVO received an average of three injections, while those with BRVO received an average of 3.6 injections.
There were no ocular or systemic side effects, the study authors said.